For example, in patients with advanced pancreatic cancer, CSF1R inhibitors in combination with PD-1/PD-L1 inhibitors may simultaneously deregulate immune checkpoint inhibition and reduce the number of immunosuppressive macrophages, thereby enhancing the anti-tumor response of T cells (86). Here, CSF1R is linked to neoplasm.